Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: The cancer-DACUS study

Journal of Clinical Oncology

Volumn 32, Issue 32, 2014, Pages 3607-3612

  Napolitano, Mariasanta ^a   Saccullo, Giorgia ^a   Malato, Alessandra ^a   Sprini, Delia ^a   Ageno, Walter ^b   Imberti, Davide ^c   Mascheroni, Doris ^d   Bucherini, Eugenio ^e   Gallucci, Pina ^f   D'Alessio, Andrea ^g   Prantera, Tullia ^h   Spadaro, Pietro ⁱ   Rotondo, Stefano ^j   Di Micco, Pierpaolo ^l   Oriana, Vincenzo ^m   Urbano, Oreste ^k   Recchia, Francesco ⁿ   Ghirarduzzi, Angelo ^o   Lo Coco, Lucio ^a   Mancuso, Salvatrice ^a   Casuccio, Alessandra ^a   Rini, Giovam Battista ^a   Siragusa, Sergio ^a   more..

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c Ospedale di Piacenza   (Italy)

^d Istituto Clinico Villa Aprica   (Italy)

^e Ospedale di Faenza   (Italy)

^f Centro Regionale Oncologico Basilicata   (Italy)

^g Policlinico San Marco   (Italy)

^h Nuovo Ospedale S Giovanni di Dio   (Italy)

ⁱ Villa Salus ^*  (Italy)

^j Centro Studi Neurolesi   (Italy)

^k Ospedale Piemonte   (Italy)

^l Ospedale Fatebenefratelli di Napoli   (Italy)

^m Azienda Ospedaliera di Reggio Calabria   (Italy)

ⁿ Ospedale Civile di Avezzano   (Italy)

^o S MARIA NUOVA HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; ANTICOAGULANT AGENT;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HODGKIN DISEASE; HORMONAL THERAPY; HUMAN; LEG; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE MYELOMA; NEOPLASM; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; RECURRENT DISEASE; STOMACH CANCER; VENOUS THROMBOEMBOLISM; AGED; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DISEASE COURSE; MORTALITY; RISK FACTOR; SURVIVAL RATE; TIME; TREATMENT OUTCOME; VASCULARIZATION; VENOUS THROMBOSIS;

AGED; ANTICOAGULANTS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LOWER EXTREMITY; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84911891890     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.7433     Document Type: Article

References (24)

1. Chew HK, Wun T, Harvey D, et al: Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458-464, 2006
2. Sørensen HT, Mellemkjaer L, Olsen JH, et al: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846-1850, 2000
3. Bick RL: Cancer-associated thrombosis. N Engl J Med 349:109-111, 2003
4. Prandoni P, Lensing AW, Piccioli A, et al: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484-3488, 2002
5. Lee AY, Levine MN, Baker RI, et al: Low molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146-153, 2003
6. Kearon C, Akl EA, Comerota AJ, et al: Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed-American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e419S-e494S, 2012
7. Hull RD, Pineo GF, Brant RF, et al: Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119:1062-1072, 2006
8. Agnelli G, Prandoni P, Santamaria MG, et al: Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis: Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 345:165-169, 2001
9. Palareti G, Leali N, Coccheri S, et al: Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT)-Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348:423-428, 1996
10. Palareti G, Cosmi B, Legnani C, et al: D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355:1780-1789, 2006
11. Prandoni P, Lensing AW, Prins MH, et al: Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 137:955-960, 2002
12. Siragusa S, Malato A, Anastasio R, et al: Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: The Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood 112:511-515, 2008
13. Siragusa S, Malato A, Saccullo G, et al: Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: The extended DACUS study. Am J Hematol 86:914-917, 2011
14. Bates SM, Jaeschke R, Stevens SM, et al: Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed-American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e351S-e418S, 2012
15. Meyer G, Marjanovic Z, Valcke J, et al: Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med 162:1729-1735, 2002
16. Prandoni P, Lensing AW, Bernardi E, et al: The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosis. Thromb Haemost 88:402-406, 2002
17. Fedullo PF, Tapson VF: Clinical practice: The evaluation of suspected pulmonary embolism. N Engl J Med 349:1247-1256, 2003
18. Kearon C: Diagnosis of pulmonary embolism. CMAJ 168:183-194, 2003
19. Brennan P, Silman A: Statistical methods for assessing observer variability in clinical measures. BMJ 304:1491-1494, 1992
20. Imberti D, Agnelli G, Ageno W, et al: Clinical characteristics and management of cancer-associated acute venous thromboembolism: Findings from the MASTER Registry. Haematologica 93:273-278, 2008
21. Klerk CP, Smorenburg SM, Otten HM, et al: The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23:2130-2135, 2005
22. Kakkar AK, Levine MN, Kadziola Z, et al: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22:1944-1948, 2004
23. Noble S, Pasi J: Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 102:S2-S9, 2010
24. Tan M, Bornais C, Rodger M: Interobserver reliability of compression ultrasound for residual thrombus after first unprovoked deep vein thrombosis. J Thromb Haemost 10:1775-1782, 2012